ARCHIVES

Professional Societes; ASCO’s Strength Is In Its Diversify, Lichtor Says

This article is from The Cancer Letter archive.

Vol. 25 No. 20 | May 21, 1999

Download PDF Visit The Full Archive

Related Articles

Urgent FDA Action Turns Power Morcellation Into Rarely Used Gynecological Procedure

December 5, 2014

Sponsors Wanted: FDA Offers Incentives For Pediatric Oncology Drug Development.

March 10, 2000

Obese Men With Benign Biopsy At High Risk for Prostate Cancer

April 26, 2013

B-27 Finds Improved CR For Taxotere Prior To Surgery

November 28, 2003

Manipulating The Therapeutic Index Clinical Trials Goal: Hellman

June 13, 1980

FDA To Issue “Complete Response” Letters To Drug Sponsors.

July 11, 2008